Boehringer Ingelheim, Rentschler Biotechnologie sign deal

Boehringer Ingelheim has signed a preferred partnership agreement with Rentschler Biotechnologie.

Under the terms of the deal, Boehringer Ingelheim customers will be able to use Rentschler’s facilities of process development and clinical supply production.

Meanwhile, Rentschler clients will be given access to Boehringer Ingelheim’s large-scale mammalian biopharmaceutical production facilities located in Biberach, Germany.

Professor Rolf Werner, corporate senior vice-president of the corporate division biopharmaceuticals at Boehringer Ingelheim, comments: “Rentschler Biotechnologie is a strong partner for process development and supply of clinical material in Europe and complements our worldwide strategic Production Alliance Network.”

Dr Wieland Wolf, vice-chairman of the Rentschler Group, adds that cooperation with Boehringer Ingelheim will result in both firms benefiting from the combined experience of the two companies as well as the easy transfer from small/medium to large-scale production.

In related news, Boehringer Ingelheim recently announced the results from the PRoFESS stroke prevention placebo controlled trial at the European Stroke Conference in Nice, France.